5-HT3 receptor antagonist MDL 72222 attenuates cocaine- and mazindol-, but not methylphenidate-induced neurochemical and behavioral effects in the rat

被引:54
作者
Kankaanpää, A [1 ]
Meririnne, E [1 ]
Seppälä, T [1 ]
机构
[1] Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, SF-00300 Helsinki, Finland
关键词
MDL; 72222; cocaine; mazindol; methylphenidate; neurochemistry reward;
D O I
10.1007/s00213-001-0939-4
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: It has previously been demonstrated that the 5-HT3 receptors located in the mesolimbic brain areas are able to modulate the dopaminergic effects of various abused drugs, including cocaine (COC). Objectives: The present experiments investigated the role of 5-HT3 receptors in the actions of selected monoamine uptake inhibitors. Methods: The ability of the 5-HT3 receptor antagonist MDL 72222 (MDL 0.1 and 1.0 mg/kg) to modify the neurochemical and behavioral changes induced by COC (20 mg/kg), mazindol (MAZ; 10 mg/kg), and methylphenidate (MP 5.0 or 10, and 20 mg/kg) was assessed with an in vivo microdialysis technique. a conditioned place preference method, and motor activity measurements. Results: MDL robustly attenuated the elevation of extracellular dopamine levels in the nucleus accumbens, acquisition of place preference, and motor activity induced by COC and MAZ, but not those induced by MP the only drug with no significant effect on 5-HT. In contrast. expression of COC-induced place preference was not attenuated by MDL. Conclusions: These results show that COC- and MAZ-induced reward-related neurochemical and behavioral effects, preferentially those implicated in development of conditioned reward, are modified by the 5-HT3 blockade. In contrast to COC and MAZ, the changes induced by MP, which has less effect on the serotonergic system, remain unchanged. Thus it appears that involvement of a serotonergic component in the mechanism of action of a drug could be a prerequisite for effective antagonism by 5-HT3 receptor blocker.
引用
收藏
页码:341 / 350
页数:10
相关论文
共 59 条
[1]  
Baker DA, 1998, SYNAPSE, V30, P181, DOI 10.1002/(SICI)1098-2396(199810)30:2<181::AID-SYN8>3.3.CO
[2]  
2-N
[3]   MDL72222, A SEROTONIN 5-HT3 RECEPTOR ANTAGONIST, BLOCKS MDMAS ABILITY TO ESTABLISH A CONDITIONED PLACE PREFERENCE [J].
BILSKY, EJ ;
REID, LD .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1991, 39 (02) :509-512
[4]   ONDANSETRON FAILS TO ATTENUATE A SCOPOLAMINE-INDUCED DEFICIT IN A STONE MAZE TASK [J].
BRATT, AM ;
KELLY, ME ;
DOMENEY, AM ;
NAYLOR, RJ ;
COSTALL, B .
NEUROREPORT, 1994, 5 (15) :1921-1924
[5]  
CAINE SB, 1995, BRAIN RES, V692, P47
[6]   5HT3 RECEPTOR ANTAGONISTS BLOCK MORPHINE-INDUCED AND NICOTINE-INDUCED BUT NOT AMPHETAMINE-INDUCED REWARD [J].
CARBONI, E ;
ACQUAS, E ;
LEONE, P ;
DICHIARA, G .
PSYCHOPHARMACOLOGY, 1989, 97 (02) :175-178
[7]   DIFFERENTIAL INHIBITORY EFFECTS OF A 5-HT3 ANTAGONIST ON DRUG-INDUCED STIMULATION OF DOPAMINE RELEASE [J].
CARBONI, E ;
ACQUAS, E ;
FRAU, R ;
DICHIARA, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 164 (03) :515-519
[8]   HABIT-FORMING ACTIONS OF NOMIFENSINE IN NUCLEUS-ACCUMBENS [J].
CARLEZON, WA ;
DEVINE, DP ;
WISE, RA .
PSYCHOPHARMACOLOGY, 1995, 122 (02) :194-197
[9]   5-HT3 receptor antagonists do not modify cocaine place conditioning or the rise in extracellular dopamine in the nucleus accumbens of rats [J].
Cervo, L ;
Pozzi, L ;
Samanin, R .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1996, 55 (01) :33-37
[10]  
CHAIT LD, 1987, J PHARMACOL EXP THER, V242, P777